Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
Hoth Therapeutics (NASDAQ: HOTH) on October 8, 2025 expanded its artificial intelligence initiative by entering an entitlement and renewal agreement for annual NVIDIA AI Enterprise Essentials licenses.
The licenses will support Hoth's GPU-powered infrastructure to enable advanced machine learning and neural network modeling for pharmaceutical research, including predictive pharmacology, toxicity modeling, multi-omic integration, clinical trial simulation, patient stratification, and real-time response monitoring. Management said the platform will be applied across development programs such as HT-001, HT-KIT, and oncology efforts to accelerate data-driven drug development and digital transformation.
Hoth Therapeutics (NASDAQ: HOTH) il 8 ottobre 2025 ha ampliato la sua iniziativa di intelligenza artificiale entrando in un accordo di entitlement e renewal per licenze annuali di NVIDIA AI Enterprise Essentials.
Le licenze sosterranno l'infrastruttura basata su GPU di Hoth per consentire avanzati modelli di machine learning e reti neurali per la ricerca farmaceutica, tra cui farmacologia predittiva, modellazione della tossicità, integrazione multi-omica, simulazione di trial clinici, stratificazione dei pazienti e monitoraggio delle risposte in tempo reale. Il management ha affermato che la piattaforma sarà applicata a vari programmi di sviluppo quali HT-001, HT-KIT e iniziative oncologiche per accelerare lo sviluppo guidato dai dati e la trasformazione digitale.
Hoth Therapeutics (NASDAQ: HOTH) el 8 de octubre de 2025 amplió su iniciativa de inteligencia artificial al firmar un acuerdo de elegibilidad y renovación para licencias anuales de NVIDIA AI Enterprise Essentials.
Las licencias respaldarán la infraestructura de Hoth impulsada por GPU para permitir modelos avanzados de aprendizaje automático y redes neuronales para la investigación farmacéutica, incluyendo farmacología predictiva, modelado de toxicidad, integración multi-ómica, simulación de ensayos clínicos, segmentación de pacientes y monitoreo de respuestas en tiempo real. La dirección afirmó que la plataforma se aplicará a programas de desarrollo como HT-001, HT-KIT y esfuerzos oncológicos para acelerar el desarrollo de fármacos basado en datos y la transformación digital.
Hoth Therapeutics (NASDAQ: HOTH)는 2025년 10월 8일에 엔타이틀먼트 및 갱신 계약으로 연간 NVIDIA AI Enterprise Essentials 라이선스를 확장했다.
라이선스는 Hoth의 GPU 기반 인프라를 지원하여 제약 연구를 위한 고급 기계 학습 및 신경망 모델링을 가능하게 하며, 예측 약리학, 독성 모델링, 다-오믹 통합, 임상 시험 시뮬레이션, 환자 계층화 및 실시간 반응 모니터링을 포함한다. 경영진은 이 플랫폼이 HT-001, HT-KIT 및 종양학 노력과 같은 개발 프로그램 전반에 적용되어 데이터 기반 약물 개발과 디지털 트랜스포메이션을 가속화할 것이라고 말했다.
Hoth Therapeutics (NASDAQ: HOTH) le 8 octobre 2025 a étendu son initiative d'intelligence artificielle en concluant un accord d'éligibilité et de renouvellement pour des licences annuelles de NVIDIA AI Enterprise Essentials.
Les licences soutiendront l'infrastructure de Hoth propulsée par GPU pour permettre des modélisations avancées en apprentissage automatique et en réseaux neuronaux pour la recherche pharmaceutique, y compris pharmacologie prédictive, modélisation de la toxicité, intégration multi-omique, simulation d'essais cliniques, stratification des patients et surveillance des réponses en temps réel. La direction a déclaré que la plateforme sera appliquée à divers programmes de développement tels que HT-001, HT-KIT et les efforts en oncologie pour accélérer le développement de médicaments fondé sur les données et la transformation numérique.
Hoth Therapeutics (NASDAQ: HOTH) hat am 8. Oktober 2025 seine KI-Initiative erweitert, indem es eine Berechtigungs- und Verlängerungsvereinbarung für jährliche Lizenzen von NVIDIA AI Enterprise Essentials abgeschlossen hat.
Die Lizenzen unterstützen die GPU-gestützte Infrastruktur von Hoth, um fortgeschrittene Modelle des maschinellen Lernens und neuronale Netzwerke für die pharmazeutische Forschung zu ermöglichen, einschließlich prädiktiver Pharmakologie, Toxizitätsmodellierung, Multi-Omik-Integration, Simulation klinischer Studien, Patientensegmentierung und Echtzeit-Reaktionsüberwachung. Das Management erklärte, dass die Plattform in Entwicklungsprogrammen wie HT-001, HT-KIT und onkologischen Initiativen eingesetzt werde, um datengetriebene Arzneimittelentwicklung und digitale Transformation zu beschleunigen.
Hoth Therapeutics (NASDAQ: HOTH) في 8 أكتوبر 2025 وسّعت مبادرتها للذكاء الاصطناعي من خلال الدخول في اتفاقية استحقاق وتجديد لرخص NVIDIA AI Enterprise Essentials سنوية.
ستدعم الرخص البنية التحتية المعتمدة على GPU لدى Hoth لتمكين نماذج متقدمة من التعلم الآلي والشبكات العصبية لأبحاث الأدوية، بما في ذلك الديناميكيات الدوائية التنبؤية، ونمذجة السمية، والتكامل متعددة-الأوميك، ومحاكاة التجارب السريرية، وتجزئة المرضى، ومراقبة الاستجابات في الوقت الفعلي. وأفاد المديرون أن المنصة ستطبق عبر برامج التطوير مثل HT-001، HT-KIT وجهود الأورام لتسريع تطوير الأدوية المعتمد على البيانات والتحول الرقمي.
Hoth Therapeutics (NASDAQ: HOTH) 于 2025年10月8日 通过签署年度 NVIDIA AI Enterprise Essentials 授权的资格与续签协议，扩大了其人工智能计划。
这些许可证将支持 Hoth 的 GPU 支撑基础设施，以实现药物研究中的高级机器学习和神经网络建模，包括预测药理学、毒性建模、多组学整合、临床试验仿真、患者分层以及实时反应监测。管理层表示，该平台将应用于开发项目，如 HT-001、HT-KIT 及肿瘤学努力，以加速数据驱动的药物开发和数字化转型。
- Secured annual NVIDIA AI Enterprise Essentials licenses
- Enables GPU-powered predictive pharmacology and toxicity modeling
- Supports clinical trial simulation and patient stratification
- None.
Insights
Hoth signed an annual NVIDIA AI Enterprise Essentials subscription to support GPU-driven ML for its R&D programs on
Hoth Therapeutics secured an annual entitlement and renewal agreement for NVIDIA AI Enterprise Essentials to run GPU-accelerated machine learning and neural-network modeling across its stated programs including HT-001, HT-KIT, and oncology efforts. The arrangement targets predictive pharmacology, toxicity modeling, multi-omic integration, clinical trial simulation, patient stratification, and real-time response monitoring using enterprise-grade GPU infrastructure.
The business mechanism is licensing cloud and on-premise AI software to scale data processing and model development for drug discovery and preclinical tasks; this removes some tooling friction and standardizes a production AI stack. Dependencies and risks include the pace at which internally generated data matures into validated models, the quality and integration of multi-omic and patient-derived datasets, and operational execution of GPU infrastructure and compliance frameworks.
Concrete items to watch include successful deployment of predictive pharmacology and toxicity models, demonstrable integration of multi-omic datasets, and any metrics or milestones for clinical trial simulation or patient stratification over the next 6–18 months. The agreement itself is a technical enabler rather than a clinical or financial outcome; progress against these implementation milestones will determine real program impact.
Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research
Under the new entitlement and renewal agreement, Hoth Therapeutics has secured annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research.
"Our continued investment in NVIDIA's AI platform reflects our long-term commitment to integrating next-generation technology across our R&D programs," said Robb Knie, CEO of Hoth Therapeutics. "We are harnessing NVIDIA's enterprise-grade AI infrastructure to accelerate the development of therapies like HT-001, HT-KIT, and our oncology programs — ultimately allowing us to make smarter, faster, and more precise decisions for patients."
The NVIDIA AI Enterprise environment will allow Hoth's scientific and data teams to:
- Deploy predictive pharmacology and toxicity models to enhance compound screening efficiency.
- Integrate multi-omic and patient-derived data for improved target discovery.
- Support clinical trial simulation, patient stratification, and real-time response monitoring.
- Leverage secure GPU-accelerated cloud infrastructure with enterprise-grade reliability and compliance.
Hoth's AI initiative complements its broader strategy of digital transformation and innovation in biotechnology, enabling partnerships with advanced AI-driven platforms and life-science data companies to optimize development timelines, reduce costs, and improve therapeutic outcomes.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-expands-artificial-intelligence-initiative-selects-nvidia-ai-enterprise-platform-302578060.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What did Hoth Therapeutics announce on October 8, 2025 regarding AI?
How will the NVIDIA AI Enterprise licenses affect HOTH's drug programs like HT-001 and HT-KIT?
Does the HOTH announcement disclose financial terms for the NVIDIA subscription?
What technical capabilities will Hoth gain from the NVIDIA AI Enterprise Essentials licenses?
Will Hoth use the NVIDIA platform for clinical trial operations, and how?
Where does HOTH plan to apply its expanded AI initiative?
